Press Release

Revenue Growth 20pctResults View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+13.1%Reaction day

₹2029.00

prior close

₹2049.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%+13.5% vs market

Pharmaceuticals peers, median of 161sector-0.3%+13.4% vs sector

On the reaction day the stock moved 13.5 pts more than Nifty Microcap 250 and 13.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.5

10m

+3.6

15m

+5.3

30m

+10.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+13.1-0.4+13.5-0.3+13.4

Next day

+17.8+1.1+16.7+0.3+17.5

+15.0+1.0+14.0+0.5+14.5

+16.8+2.6+14.1+1.8+14.9

+22.7+4.2+18.5+3.1+19.6

+22.1+4.2+17.9+3.6+18.5

+14.5-0.5+15.0+1.6+12.9

15d

+13.3+0.9+12.3+1.7+11.6

+6.7+1.5+5.3+2.5+4.2

+13.1+9.1+4.0+5.7+7.4

+37.4+8.1+29.3+7.8+29.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

RPG Life Sciences reported strong Q4 FY26 results with revenue of Rs. 176.9 crores, up 23.6% Y-o-Y, driven by robust Domestic Formulations growth of 18.2% (1.8x market growth) and exceptional API division recovery of 144.3% after the January 2025 fire incident. Full year FY26 revenue stood at Rs. 707.5 crores, an 8.3% increase from Rs. 653.4 crores in FY25. The company maintained healthy EBITDA margins of 25.6% in Q4 and 24.4% for FY26. RPG Life Sciences emerged as the 4th fastest growing pharma company in India, with Domestic Formulations (70% of sales) delivering 13.7% growth vs IPM's 8.6%. The Board recommended a dividend of Rs. 24 per share (300%).

Likely market impact

Strong quarterly growth beating market expectations and healthy margins indicate solid operational performance. The API division's recovery from the fire incident removes uncertainty. The generous 300% dividend payout signals confidence in the company's financial health, which could be positive for shareholder returns.